Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine

J Fam Pract. 2020 Jan/Feb;69(1 Suppl):S8-S12.

Authors

Andrew M Blumenfeld¹, Lars Edvinsson², Abhijeet Jakate³, Pradeep Banerjee³

Affiliations

¹ Headache Center of Southern California, The Neurology Center, Carlsbad, CA, USA.
² Department of Internal Medicine, Institute of Clinical Sciences, Lund University Hospital, Lund, Sweden.
³ Allergan plc, Madison, NJ, USA.

PMID: 32053714

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease / therapy*
Adolescent
Adult
Aged
Aged, 80 and over
Calcitonin Gene-Related Peptide Receptor Antagonists / pharmacology*
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use*
Female
Humans
Male
Middle Aged
Migraine Disorders / diagnosis*
Migraine Disorders / drug therapy*
Migraine Disorders / physiopathology*
Pyridines / pharmacology*
Pyridines / therapeutic use*
Pyrroles / pharmacology*
Pyrroles / therapeutic use*
Risk Factors
Young Adult

Substances

Calcitonin Gene-Related Peptide Receptor Antagonists
Pyridines
Pyrroles
ubrogepant